Cell-autonomous GP130 activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment
Christina Sternberg, Martin Raigel, Tanja Limberger, Karolína Trachtová, Michaela Schlederer, Desiree Lindner, Petra Kodajova, Jiaye Yang, Roman Ziegler, Jessica Kalla, Stefan Stoiber, Saptaswa Dey, Daniela Zwolanek, Heidi Anne Neubauer, Monika Oberhuber, , Lukas Kenner
This study shows that activating GP130 in prostate epithelial cells suppresses tumor growth through senescence and immune activation, suggesting a new therapeutic approach.
Molecular Cancer · Oct 31, 2024Peer-reviewedCancer Biology